Meta-analysis finds lower incidence of haematological toxicity versus similar drugs.

Background

• The immune checkpoint inhibitor nivolumab is approved in the US and Europe for at least 10 cancer types, including melanoma, non-small cell lung cancer, renal cell carcinoma, and gastric cancer.
• Nivolumab works by inhibiting the immunosuppressive molecule programmed cell...